생명과학 분야 생성형 AI 시장 : 규모, 점유율, 성장, 산업 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of Generative AI in Life Sciences Market

The global Generative AI in Life Sciences Market is witnessing remarkable growth as pharmaceutical companies, biotechnology firms, and research organizations increasingly adopt artificial intelligence to accelerate drug discovery, streamline clinical trials, enhance regulatory documentation, and improve scientific decision-making. According to the report, the global Generative AI in Life Sciences Market was valued at USD 1.18 billion in 2025. The market is projected to grow from USD 1.60 billion in 2026 to USD 18.20 billion by 2034, exhibiting a CAGR of 35.52% during the forecast period. In 2025, North America dominated the market with a 46.61% share, supported by advanced healthcare infrastructure, strong pharmaceutical R&D investments, and rapid adoption of AI-powered drug development platforms.

Generative AI in life sciences includes AI-powered software, platforms, and models that generate scientific insights, automate documentation, optimize molecular design, and support data-driven decision-making across the pharmaceutical and biotechnology industries.

Market Definition and Scope

Generative AI is transforming life sciences by enabling organizations to process vast volumes of genomic, molecular, imaging, regulatory, and clinical data efficiently. These AI solutions assist researchers in identifying drug candidates, designing clinical trials, generating regulatory documents, summarizing scientific literature, and improving knowledge management.

The market covers software platforms, AI services, cloud-based and on-premise deployments, large language models (LLMs), natural language processing technologies, generative molecular models, and machine learning applications. Its scope extends across pharmaceutical & biotechnology companies, contract research organizations (CROs), research institutes, diagnostics companies, and other healthcare organizations seeking faster and more efficient research workflows.

Market Dynamics

Drivers

The growing volume of genomic, molecular, and clinical data is one of the primary factors driving market expansion. Traditional analytical methods often struggle to process increasingly complex datasets, whereas generative AI enables rapid data interpretation, target identification, molecule generation, and optimized clinical trial planning. Pharmaceutical companies are adopting AI platforms to reduce development costs, accelerate research timelines, and improve success rates.

Trends

A key market trend is the rising adoption of AI copilots across life sciences research. These intelligent assistants help scientists summarize research findings, compare experimental data, generate reports, and retrieve scientific knowledge from multiple data sources. Companies are increasingly integrating AI copilots directly into laboratory and research workflows, improving productivity while reducing manual documentation efforts.

Restraints

Regulatory uncertainty remains a significant restraint for market growth. Healthcare regulators require AI-generated outputs to be transparent, validated, explainable, and fully traceable before being used in scientific or regulatory submissions. Concerns regarding AI hallucinations, inaccurate outputs, and compliance issues continue to limit the adoption of fully autonomous AI systems.

Opportunities

Growing use of generative AI in real-world evidence (RWE) and pharmacovigilance presents significant growth opportunities. AI-powered platforms help pharmaceutical companies analyze patient records, adverse event reports, and post-market surveillance data, enabling faster safety monitoring and improved evidence generation.

Segmentation Analysis

By component, software and platforms dominate the market due to increasing demand for scalable AI infrastructure supporting drug discovery, scientific research, and enterprise knowledge management. Services are expected to witness strong growth as organizations seek implementation, consulting, and integration support.

By deployment, cloud-based solutions hold the largest market share because they provide scalable computing resources, secure collaboration, continuous AI model updates, and easier integration across research organizations.

By technology, Large Language Models (LLMs) dominate the market owing to their extensive use in medical writing, regulatory documentation, literature reviews, clinical protocol development, and scientific content generation.

By product type, standalone solutions lead the market as pharmaceutical companies prefer testing dedicated AI applications before integrating them into enterprise-wide research systems.

By application, drug discovery and design account for the largest share due to heavy investments in AI-enabled molecule generation, target identification, and biologics research. By end user, pharmaceutical and biotechnology companies remain the leading adopters as they possess the resources and data necessary for large-scale AI implementation.

Regional Insights

North America leads the global market with a valuation of USD 0.55 billion in 2025, driven by strong AI adoption, advanced cloud infrastructure, and substantial pharmaceutical research investments. Europe remains the second-largest market due to increasing adoption of responsible AI technologies and regulatory compliance initiatives. Asia Pacific is emerging rapidly with growing biotechnology investments, expanding pharmaceutical manufacturing, and accelerating healthcare digitalization. Latin America and the Middle East & Africa are expected to witness steady growth as healthcare organizations increasingly adopt AI-enabled research and clinical solutions.

Competitive Landscape

The market is moderately fragmented, with leading companies focusing on AI innovation, strategic collaborations, and product development. Major players include NVIDIA Corporation, Oracle Corporation, Microsoft Corporation, IQVIA Inc., Veeva Systems Inc., Alphabet Inc., Benchling Inc., Insilico Medicine, Recursion Pharmaceuticals, and Tempus AI. These companies continue investing in scientific AI models, enterprise cloud platforms, and AI-powered drug discovery technologies to strengthen their competitive position.

Report Coverage

The report provides a comprehensive analysis of the global Generative AI in Life Sciences Market, including market size for 2025, 2026, and 2034, market dynamics, growth drivers, emerging trends, restraints, opportunities, segmentation by component, deployment, technology, product type, application, and end user. It also includes regional analysis, competitive landscape, company profiles, and recent industry developments shaping the future of the market.

Conclusion

The global Generative AI in Life Sciences Market is poised for exceptional expansion, growing from USD 1.18 billion in 2025 to USD 1.60 billion in 2026, and reaching USD 18.20 billion by 2034. Rising adoption of AI-powered drug discovery platforms, increasing pharmaceutical R&D investments, rapid digital transformation, and growing demand for efficient scientific workflows will continue driving market growth. Despite regulatory and integration challenges, continuous technological advancements and expanding AI applications across life sciences are expected to create significant long-term opportunities for market participants.

Segmentation By Component, Deployment, Technology, Product Type, Application, End User, and Region

By Component * Software/Platforms

• Services

By Deployment * Cloud-Based

• On-Premise
• Hybrid

By Technology * Large Language Models (LLMs)

• Natural Language Processing (NLP)
• Generative Molecular/Protein Models
• Machine Learning & Deep Learning
• Others

By Product Type * Standalone

• Integrated

By Application * Drug Discovery & Design

• Clinical Trial Design & Operations
• Regulatory Writing & Submissions
• Medical Affairs & Scientific Content
• Pharmacovigilance
• Commercial & Market Access Content
• Others

By End User * Pharmaceutical & Biotechnology Companies

• CROs
• Academic & Research Institutes
• MedTech/Diagnostics Companies
• Others

By Region * North America (By Component, Deployment, Technology, Product Type, Application, End User, and Country)

• U.S.
• Canada
• Europe (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Overview of Technological Advancements
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.4. Key Start Ups, By Regions/Countries

5. Global Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Component
  • 5.1.1. Software/Platforms
  • 5.1.2. Services
• 5.2. Market Analysis, Insights and Forecast - By Deployment
  • 5.2.1. Cloud-Based
  • 5.2.2. On-Premise
  • 5.2.3. Hybrid
• 5.3. Market Analysis, Insights and Forecast - By Technology
  • 5.3.1. Large Language Models (LLMs)
  • 5.3.2. Natural Language Processing (NLP)
  • 5.3.3. Generative Molecular/Protein Models
  • 5.3.4. Machine Learning & Deep Learning
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Product Type
  • 5.4.1. Standalone
  • 5.4.2. Integrated
• 5.5. Market Analysis, Insights and Forecast - By Application
  • 5.5.1. Drug Discovery & Design
  • 5.5.2. Clinical Trial Design & Operations
  • 5.5.3. Regulatory Writing & Submissions
  • 5.5.4. Medical Affairs & Scientific Content
  • 5.5.5. Pharmacovigilance
  • 5.5.6. Commercial & Market Access Content
  • 5.5.7. Others
• 5.6. Market Analysis, Insights and Forecast - By End User
  • 5.6.1. Pharmaceutical & Biotechnology Companies
  • 5.6.2. CROs
  • 5.6.3. Academic & Research Institutes
  • 5.6.4. MedTech/Diagnostics Companies
  • 5.6.5. Others
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Component
  • 6.1.1. Software/Platforms
  • 6.1.2. Services
• 6.2. Market Analysis, Insights and Forecast - By Deployment
  • 6.2.1. Cloud-Based
  • 6.2.2. On-Premise
  • 6.2.3. Hybrid
• 6.3. Market Analysis, Insights and Forecast - By Technology
  • 6.3.1. Large Language Models (LLMs)
  • 6.3.2. Natural Language Processing (NLP)
  • 6.3.3. Generative Molecular/Protein Models
  • 6.3.4. Machine Learning & Deep Learning
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Product Type
  • 6.4.1. Standalone
  • 6.4.2. Integrated
• 6.5. Market Analysis, Insights and Forecast - By Application
  • 6.5.1. Drug Discovery & Design
  • 6.5.2. Clinical Trial Design & Operations
  • 6.5.3. Regulatory Writing & Submissions
  • 6.5.4. Medical Affairs & Scientific Content
  • 6.5.5. Pharmacovigilance
  • 6.5.6. Commercial & Market Access Content
  • 6.5.7. Others
• 6.6. Market Analysis, Insights and Forecast - By End User
  • 6.6.1. Pharmaceutical & Biotechnology Companies
  • 6.6.2. CROs
  • 6.6.3. Academic & Research Institutes
  • 6.6.4. MedTech/Diagnostics Companies
  • 6.6.5. Others
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Component
  • 7.1.1. Software/Platforms
  • 7.1.2. Services
• 7.2. Market Analysis, Insights and Forecast - By Deployment
  • 7.2.1. Cloud-Based
  • 7.2.2. On-Premise
  • 7.2.3. Hybrid
• 7.3. Market Analysis, Insights and Forecast - By Technology
  • 7.3.1. Large Language Models (LLMs)
  • 7.3.2. Natural Language Processing (NLP)
  • 7.3.3. Generative Molecular/Protein Models
  • 7.3.4. Machine Learning & Deep Learning
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Product Type
  • 7.4.1. Standalone
  • 7.4.2. Integrated
• 7.5. Market Analysis, Insights and Forecast - By Application
  • 7.5.1. Drug Discovery & Design
  • 7.5.2. Clinical Trial Design & Operations
  • 7.5.3. Regulatory Writing & Submissions
  • 7.5.4. Medical Affairs & Scientific Content
  • 7.5.5. Pharmacovigilance
  • 7.5.6. Commercial & Market Access Content
  • 7.5.7. Others
• 7.6. Market Analysis, Insights and Forecast - By End User
  • 7.6.1. Pharmaceutical & Biotechnology Companies
  • 7.6.2. CROs
  • 7.6.3. Academic & Research Institutes
  • 7.6.4. MedTech/Diagnostics Companies
  • 7.6.5. Others
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Component
  • 8.1.1. Software/Platforms
  • 8.1.2. Services
• 8.2. Market Analysis, Insights and Forecast - By Deployment
  • 8.2.1. Cloud-Based
  • 8.2.2. On-Premise
  • 8.2.3. Hybrid
• 8.3. Market Analysis, Insights and Forecast - By Technology
  • 8.3.1. Large Language Models (LLMs)
  • 8.3.2. Natural Language Processing (NLP)
  • 8.3.3. Generative Molecular/Protein Models
  • 8.3.4. Machine Learning & Deep Learning
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Product Type
  • 8.4.1. Standalone
  • 8.4.2. Integrated
• 8.5. Market Analysis, Insights and Forecast - By Application
  • 8.5.1. Drug Discovery & Design
  • 8.5.2. Clinical Trial Design & Operations
  • 8.5.3. Regulatory Writing & Submissions
  • 8.5.4. Medical Affairs & Scientific Content
  • 8.5.5. Pharmacovigilance
  • 8.5.6. Commercial & Market Access Content
  • 8.5.7. Others
• 8.6. Market Analysis, Insights and Forecast - By End User
  • 8.6.1. Pharmaceutical & Biotechnology Companies
  • 8.6.2. CROs
  • 8.6.3. Academic & Research Institutes
  • 8.6.4. MedTech/Diagnostics Companies
  • 8.6.5. Others
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Component
  • 9.1.1. Software/Platforms
  • 9.1.2. Services
• 9.2. Market Analysis, Insights and Forecast - By Deployment
  • 9.2.1. Cloud-Based
  • 9.2.2. On-Premise
  • 9.2.3. Hybrid
• 9.3. Market Analysis, Insights and Forecast - By Technology
  • 9.3.1. Large Language Models (LLMs)
  • 9.3.2. Natural Language Processing (NLP)
  • 9.3.3. Generative Molecular/Protein Models
  • 9.3.4. Machine Learning & Deep Learning
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Product Type
  • 9.4.1. Standalone
  • 9.4.2. Integrated
• 9.5. Market Analysis, Insights and Forecast - By Application
  • 9.5.1. Drug Discovery & Design
  • 9.5.2. Clinical Trial Design & Operations
  • 9.5.3. Regulatory Writing & Submissions
  • 9.5.4. Medical Affairs & Scientific Content
  • 9.5.5. Pharmacovigilance
  • 9.5.6. Commercial & Market Access Content
  • 9.5.7. Others
• 9.6. Market Analysis, Insights and Forecast - By End User
  • 9.6.1. Pharmaceutical & Biotechnology Companies
  • 9.6.2. CROs
  • 9.6.3. Academic & Research Institutes
  • 9.6.4. MedTech/Diagnostics Companies
  • 9.6.5. Others
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Component
  • 10.1.1. Software/Platforms
  • 10.1.2. Services
• 10.2. Market Analysis, Insights and Forecast - By Deployment
  • 10.2.1. Cloud-Based
  • 10.2.2. On-Premise
  • 10.2.3. Hybrid
• 10.3. Market Analysis, Insights and Forecast - By Technology
  • 10.3.1. Large Language Models (LLMs)
  • 10.3.2. Natural Language Processing (NLP)
  • 10.3.3. Generative Molecular/Protein Models
  • 10.3.4. Machine Learning & Deep Learning
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Product Type
  • 10.4.1. Standalone
  • 10.4.2. Integrated
• 10.5. Market Analysis, Insights and Forecast - By Application
  • 10.5.1. Drug Discovery & Design
  • 10.5.2. Clinical Trial Design & Operations
  • 10.5.3. Regulatory Writing & Submissions
  • 10.5.4. Medical Affairs & Scientific Content
  • 10.5.5. Pharmacovigilance
  • 10.5.6. Commercial & Market Access Content
  • 10.5.7. Others
• 10.6. Market Analysis, Insights and Forecast - By End User
  • 10.6.1. Pharmaceutical & Biotechnology Companies
  • 10.6.2. CROs
  • 10.6.3. Academic & Research Institutes
  • 10.6.4. MedTech/Diagnostics Companies
  • 10.6.5. Others
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. NVIDIA Corporation
  • 11.2.2. IQVIA Inc.
  • 11.2.3. Oracle Corporation
  • 11.2.4. Veeva Systems Inc.
  • 11.2.5. Microsoft Corporation
  • 11.2.6. Alphabet Inc.
  • 11.2.7. Benchling, Inc.
  • 11.2.8. Insilico Medicine
  • 11.2.9. Recursion Pharmaceuticals, Inc.
  • 11.2.10. Tempus AI, Inc.